University of Exeter
Browse

Coxsackievirus infection induces direct pancreatic β cell killing but poor antiviral CD8+ T cell responses.

Download (6.2 MB)
journal contribution
posted on 2025-08-02, 12:30 authored by F Vecchio, A Carré, D Korenkov, Z Zhou, P Apaolaza, S Tuomela, O Burgos-Morales, I Snowhite, J Perez-Hernandez, B Brandao, G Afonso, C Halliez, J Kaddis, SC Kent, M Nakayama, SJ Richardson, J Vinh, Y Verdier, J Laiho, R Scharfmann, M Solimena, Z Marinicova, E Bismuth, N Lucidarme, J Sanchez, C Bustamante, P Gomez, S Buus, nPOD-Virus Working Group, S You, A Pugliese, H Hyoty, T Rodriguez-Calvo, M Flodstrom-Tullberg, R Mallone
Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β cell autoimmunity and type 1 diabetes. We investigated how CVB affects human β cells and anti-CVB T cell responses. β cells were efficiently infected by CVB in vitro, down-regulated human leukocyte antigen (HLA) class I, and presented few, selected HLA-bound viral peptides. Circulating CD8+ T cells from CVB-seropositive individuals recognized a fraction of these peptides; only another subfraction was targeted by effector/memory T cells that expressed exhaustion marker PD-1. T cells recognizing a CVB epitope cross-reacted with β cell antigen GAD. Infected β cells, which formed filopodia to propagate infection, were more efficiently killed by CVB than by CVB-reactive T cells. Our in vitro and ex vivo data highlight limited CD8+ T cell responses to CVB, supporting the rationale for CVB vaccination trials for type 1 diabetes prevention. CD8+ T cells recognizing structural and nonstructural CVB epitopes provide biomarkers to differentially follow response to infection and vaccination.

Funding

115797 (INNODIA)

22/0006504

3-PDF-2020-942-A-N

3-SRA-2017-492-A-N

945268 (INNODIA HARVEST)

ANR-19-CE15-0014-01

Agence Nationale de la Recherche

EQU20193007831

Federal Ministry for Education and Research (BMBF) to the German Center for Diabetes Research (DZD e.V.)

Fondation pour la Recherche Medicale

HANDEL-I; RRID:SCR_021947

Human Atlas of Neonatal Development and Early Life Immunity program

Innovative Medicines Initiative 2 Joint Undertaking

Juvenile Diabetes Research Foundation

National Institutes for Health Research (NIH)

Novo Nordisk

R01DK099317

Steve Morgan Foundation

Strategic Research Program in Diabetes at Karolinska Institutet

Swedish Child Diabetes Foundation

Swedish Research Council

History

Related Materials

Rights

© 2024 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY).

Notes

This is the final version. Available on open acess from the American Association for the Advancement of Science via the DOI in this record. Data and materials availability: Immunopeptidomics datasets have been deposited under PRIDE: PXD042711. All other data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. All unique/stable reagents generated in this study can be provided by R.M. pending scientific review and a completed materials transfer agreement. Requests should be submitted to roberto.mallone@ inserm.fr.

Journal

Science Advances

Publisher

American Association for the Advancement of Science

Place published

United States

Version

  • Version of Record

Language

en

FCD date

2024-08-05T14:51:58Z

FOA date

2024-08-05T15:06:08Z

Citation

Vol. 10, No. 10, article eadl1122

Department

  • Clinical and Biomedical Sciences

Usage metrics

    University of Exeter

    Categories

    No categories selected

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC